Cromin's

Carbazochrome

Method of action: Antihemorrhagics

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cromin's

The medication Cromin's is an established pharmaceutical preparation whose core purpose is to assist in the management and prevention of bleeding, classifying it as a hemostatic agent or antihemorrhagic agent. It is clinically recognized for its targeted action on the microcirculation, supporting its use in scenarios of compromised capillary health.

Property	Description
Active Ingredient	Carbazochrome (Adrenochrome Semicarbazone)
Form	Tablet (oral), Solution (parenteral injection)
Pharmacological Class	Systemic Hemostatic Agent (ATC: B02BX)
General Purpose	Capillary stabilization to control blood seepage
Origin	Synthetic, derived from adrenaline oxidation

Cromin's: A Systemic Hemostatic Agent

Cromin's is defined by its active ingredient, Carbazochrome, which acts internally across the circulatory system to support microvascular integrity. The substance is classified under the Anatomical Therapeutic Chemical (ATC) system as B02BX02, placing it within the category of other systemic hemostatics. This systemic classification indicates that the drug’s intended therapeutic effect occurs internally, supporting the body's entire circulatory system. The drug is supplied both as a common tablet for oral administration and as a sterile solution for parenteral injection, offering the prescribing physician a choice based on the necessity for immediate systemic delivery.

The Composition and Origin of Carbazochrome

The active substance, Carbazochrome, is chemically identified as Adrenochrome Semicarbazone. This compound is synthetic, created through the oxidation of the naturally occurring substance adrenaline, a manufacturing process that yields a standardized and consistent chemical profile. Carbazochrome's core identity lies in its distinct structure, and the preparation is characteristically a single active ingredient product, focusing its therapeutic effect solely on the properties of this specific molecule.

General Purpose: Stabilizing Capillaries to Control Bleeding

The general purpose of Cromin's is to address localized bleeding by strengthening the walls of the smallest blood vessels. Carbazochrome functions as a capillary stabilizer, working to increase the resistance of the vessel walls and reduce excessive vascular hyperpermeability. This specific action on the microcirculation provides the general benefit of helping to stop or prevent blood loss that originates from fragile or overly permeable capillaries, a function that is often employed in preparations for or recovery from certain surgical procedures to support general hemostasis.

What side effects are possible with Cromin's?

The safety characteristics of Cromin's (Carbazochrome) are defined by government regulatory documents, which classify adverse reactions according to the body system affected and their reported incidence.

Adverse Reaction Scope

The most commonly reported adverse reactions are classified within Gastrointestinal disorders (e.g., anorexia and stomach discomfort) and Skin and Subcutaneous Tissue disorders (e.g., rash). These effects represent the more frequent, though typically non-serious, safety observations found in official labeling.

Classification	Examples of Reactions	Affected System-Organ Class
Most Commonly Reported	Anorexia, Stomach discomfort, Rash	Gastrointestinal, Skin and Subcutaneous Tissue
Rarely Seen	Shock, Anaphylaxis	General Disorders

Serious Adverse Reactions and Safety Notes

The regulatory label explicitly documents rarely seen serious adverse reactions, which include the potential for Shock and Anaphylaxis. The official texts describe initial symptoms that may precede these serious events, such as a pale face, cold sweat, or dizziness on standing up.

Safety-related constraints specify that caution is required in patients who have a known allergy or hypersensitivity to Carbazochrome or its components. Additionally, the regulatory information includes population-specific cautions, noting that special consideration is needed for use in individuals who are pregnant or breastfeeding.

Two non-pathological safety notes are included: the urine may change color to orange-yellow, and the medicine may potentially affect laboratory test values, necessitating disclosure during testing.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Cromin's (Carbazochrome) primarily presents as an exaggeration of known adverse effects. These manifestations, which require monitoring and supportive care, typically affect the gastrointestinal system and may include severe symptoms such as intense nausea, vomiting, and diarrhea. The regulatory profile does not explicitly cite unique, life-threatening complications directly attributable to acute overdose. The regulatory context notes that the primary factor is the accidental excess of the prescribed dose.

When to Seek Immediate Medical Help

Regulatory labeling explicitly mandates that immediate medical attention must be sought if an overdose is suspected or following the consumption of an excess dose. This ensures the prompt initiation of the management protocol described in the official prescribing information. Patients or caregivers must consult with a doctor or pharmacist immediately after an overdose event.

Official Management Protocol

Due to the constraints documented in the prescribing information, no specific antidote is known for Carbazochrome overdose. Therefore, the required treatment approach is designated as strictly symptomatic and supportive treatment. This involves clinical measures to maintain the patient's physiological stability and address emergent signs. The official guidance notes that hospital monitoring may be required following initial management for continuous observation.

Therapeutic Uses of Cromin's

What Cromin's Treats: Main Uses and Benefits

The therapeutic domain of Cromin's (Carbazochrome) is used across domains where additional symptomatic support is needed for managing symptoms related to microvascular bleeding. The medication is considered relevant for conditions involving capillary and parenchymal hemorrhage, such as bleeding in the gastrointestinal tract, to support patients with specific conditions like thrombocytopenic purpura, and during procedures like tonsillectomy or dental extractions. The drug may be part of symptomatic management for these types of bleeding and associated symptoms.

It is applied when patients experience recurrent bleeding episodes like frequent nosebleeds (epistaxis) or minor internal blood seepage. Providing support that may help ease the overall symptom load, Cromin's assists with managing symptoms that create noticeable physiological strain and interfere with daily functioning.

“This supportive agent may help patients cope more steadily with symptom fluctuations associated with bleeding tendencies and surgical blood loss.”

The medication is commonly used in clinical settings as supportive therapy during and after procedures, where its primary therapeutic benefit is in the management of blood loss during the perioperative phase. This may assist with reducing the reliance on blood transfusions and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Microvascular Blood Seepage Cromin's is applied in scenarios where symptoms are linked to organ-specific functional stress (e.g., urinary bleeding) or recurrent episodic manifestations (e.g., frequent epistaxis). It supports the patient during difficult episodes by easing distress and assists with maintaining a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Official Eligibility Profile for Cromin's (Carbazochrome)

The eligibility profile for Cromin's is defined by authoritative regulatory labeling, establishing clear restrictions and contraindications for specific populations.

Eligibility Criteria	Regulatory Status
Absolute Contraindication	Use is strictly prohibited for patients with a known hypersensitivity or allergy to Carbazochrome (Adrenochrome Semicarbazone) or any excipients in the product's composition.
Comorbidity Restriction	Use is highly restricted or contraindicated in patients with severe hepatic disease or impaired liver function. Caution is advised for patients with a history of thrombotic events or existing renal impairment.
Pregnancy/Lactation	Not Recommended. The drug should only be used if the potential benefit to the mother significantly outweighs the possible risks, as safety in pregnant or nursing mothers is not conclusively established.
Age-Group Restrictions	Adults are the standard eligible population. Elderly patients require caution due to increased physiological sensitivity. Pediatric patients are eligible, but specific formulations (injections) have strictly limited maximum doses for infants and young children.

These official label-based rules systematically classify all populations who can, cannot, or may conditionally use the medicine, based on their pre-existing health status, age, or physiological state.

What should I know about interactions with other medicines?

Cromin's Interactions with other medicines and products

This section outlines the officially documented interaction profile for Cromin's (Carbazochrome) as described in government regulatory documents and approved prescribing information. This information is limited to formal regulatory statements and is not a comprehensive guide to usage or safety.

Documented Pharmacodynamic Interactions

The primary interactions formally noted in regulatory summaries involve medicines that affect blood coagulation, classifying them as pharmacodynamic interactions. Co-administration of these medicines may alter the intended clinical effect.

Anticoagulants (e.g., Warfarin, Heparin): Official documents state that co-administration may result in the diminishment or enhancement of the medicinal effects of either Cromin's or the anticoagulant.
Fibrinolytic Agents (e.g., Streptokinase): Interaction with these medicines is documented as potentially altering the desired therapeutic outcome due to opposing or complementary actions on the clotting process.
Antacids: Certain regulatory summaries list specific antacids, such as Aluminium Hydroxide, as substances that may interact with Carbazochrome.

Regulatory Status of Other Interactions

Interaction Type	Regulatory Documentation Status
Contraindicated Combinations	No combinations are formally classified as prohibited based on interaction risk.
Pharmacokinetic Interactions (CYP, Transporters)	No explicit information is documented regarding effects on drug-metabolizing enzymes (CYP) or transporters.
Timing Requirements	No mandatory timing or dose separation rules are explicitly stated in the prescribing information.
Alcohol Interaction	The interaction between Cromin's and alcohol is officially listed as unknown.

Mechanism of Action

Mast Cell Stabilization and Signaling Dampening

Cromin's exerts its primary effect by acting directly on mast cells, stabilizing their membranes to prevent the process of degranulation. This targeted intervention is used to modulate the overactive release of specific inflammatory mediators, affecting excessive cellular signaling within specific regulatory systems.

Interference with Molecular Mediator Cascades

The core mechanism involves interrupting molecular cascades by suppressing the signaling events that cause mediator discharge, such as histamine and leukotrienes. This action is relevant in biological systems where rapid, excessive release of these transmitters dominates, and it modifies early molecular steps that shape downstream physiological outcomes.

Consequences of Mediator Modulation in Downstream Pathways

By effectively reducing the local concentration of inflammatory substances, Cromin's establishes conditions conducive to a more modulated state within the targeted pathways. This action influences the maintenance of regulated physiological responses, affects the magnitude of consequences associated with excessive mediator activity, and results in physiological adjustments corresponding to the drug's mechanistic profile.

Dosage and Administration Information

How to Use Cromin's

Cromin's (Carbazochrome) is used according to specific, standardized instructions detailing its route, dose, and frequency to ensure proper administration. This section describes the standard usage patterns.

Administration Routes and Forms

Cromin's is administered through two primary methods: oral intake via the tablet form, and parenteral injection via the solution form. The parenteral route includes administration via Intramuscular (IM) injection, Subcutaneous (SC) injection, Intravenous (IV) injection, or IV infusion.

Standard Dosing Regimens and Frequency

The dosage schedule is based on the route of administration:

Administration Route	Standard Adult Dose	Frequency	Special Condition
Oral Tablet	10 mg to 30 mg at one time	Three times daily (TID)	May be taken independently of food
Parenteral (IM/SC)	10 mg of active ingredient	Once daily	Administered by healthcare professional

Standard oral and parenteral dosing ranges follow established clinical guidelines. The use of the injectable form is restricted to administration within a clinical setting.

Use Pattern and Procedural Guidance

The overall duration of treatment is not fixed but is determined by the necessity for continued capillary support, adjusted according to the patient's symptoms. Dosage adjustments may be made based on age and symptom severity. Patients are typically instructed not to discontinue the medicine suddenly unless directed by a professional. If a dose is missed, individuals are advised not to take two doses at one time but to return to the regular scheduled regimen.

Recent Clinical Evidence

Research evidence / Overview of studies

This section provides an overview of the key research that has examined the drug's profile.

How the Drug Was Studied

The trials investigated the drug's profile and effects on various symptoms. Clinical research has been conducted to examine the drug's impact on various measured outcomes.

Phase 1 Trials (Initial Dose and Tolerance): Early-stage research focused on assessing the general tolerance and initial pharmacokinetic profile of the drug in healthy volunteers.
Phase 2 Trials (Exploring Measured Effect): Research in this phase explored a range of doses to identify one that was generally tolerated while also showing early associations with a measured effect.
Phase 3 Trials (Large-Scale Comparison): These large-scale studies aimed to compare the drug's effect to a placebo or an active comparator.

Key Findings from Controlled Trials

Studies have explored whether the drug is associated with changes in chronic pain measures. The primary outcomes focused on changes in specific standardized scores.

Study A: Randomized Control Trial Findings

One study (RCT, N=500) reported changes in the measured outcomes over a 6-month period.

Outcome Type	Cromin's Group Result	Placebo Group Result
VAS pain score change (10-point scale)	2.5 point decrease	0.8 point decrease
Functional Status Questionnaire Score	60% reported specific change	35% reported specific change

This study's interpretation was that the results were relevant to the evaluation of this drug.

Safety and Long-Term Research

Studies examined the relationship between the study drug administration schedule and the onset of measured patient reports. Reported adverse events in the study were characterized by the researchers, and long-term administration was monitored in this specific research population.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cromin's (FAQ)

Q: Are the common side effects of Cromin's serious?

Official safety documents list the most commonly reported side effects, such as stomach discomfort or rash, separately from the documented serious, but rare, adverse reactions, such as shock or anaphylaxis. The common effects are not typically categorized as serious in the same manner as the rare events. Regulatory classification is based on reported incidence and severity within clinical populations.

Q: Is it normal to feel [vague side effect, e.g., slightly tired] when taking Cromin's?

Official documentation does not typically include general symptoms like fatigue or tiredness among the most frequently reported side effects. If a person experiences new or concerning symptoms while taking the medicine, concerns about symptoms not listed in the product label are typically discussed with a healthcare professional.

Q: Does Cromin's interact with common pain relievers like ibuprofen?

The official product information advises caution regarding the use of Cromin's alongside other medicines that may affect blood clotting, such as anticoagulants. Regulatory information advises that any combination of Cromin’s with nonsteroidal anti-inflammatory drugs (NSAIDs) should be determined by a healthcare provider.

Q: What if I'm taking multiple vitamins or herbal products with Cromin's?

Official regulatory guidance requires disclosure of all concomitant products, including dietary supplements and herbal items, to a healthcare professional. This is because some non-prescription products may potentially alter the intended effects described for Cromin's.

Q: Will Cromin's affect my ability to drive or operate machinery?

Official regulatory documents indicate that Cromin's is not usually associated with effects that impair the ability to drive or operate heavy machinery. If an individual experiences side effects like dizziness or lightheadedness, which can affect coordination, they should seek clarification from a health professional before driving or operating machinery.

Q: How quickly should I expect Cromin's to start working?

Pharmacokinetic studies, which examine how the medicine moves through the body, indicate that the concentration of the active ingredient typically reaches its highest level in the bloodstream within 30 minutes to one hour after taking an oral dose.

Q: How long does the effect of one dose of Cromin's typically last?

Based on pharmacokinetic studies, the biological half-life of the active ingredient, Carbazochrome, is reported to be about 1.5 hours after a single oral dose. This metric, found in regulatory studies, describes the rate at which the active substance is processed and eliminated by the body.

Q: What is the difference between the immediate-release and extended-release forms of Cromin's?

The standard oral form is typically immediate-release. Manufacturing documents also describe specific extended-release or slow-release tablet formulations. These specialized forms are engineered to release the active substance at a modified rate compared to the standard tablet.

Q: Can Cromin's be crushed or split if the person has trouble swallowing?

Some specialized extended-release tablets are described in formulation documents as being scored or made as a 'cut sheet' to allow for division. Regulatory safety principles advise against modifying a tablet by crushing or splitting unless the product’s label or a prescribing professional explicitly permits it.

Q: Is Cromin's the same kind of drug as [similar common drug name]?

Cromin's contains the active ingredient Carbazochrome, and it is officially classified as a systemic hemostatic agent. Its classification places it in a category of specialized medicines that assist in maintaining the integrity of small blood vessels.

Q: Why do doctors prescribe Cromin's instead of an over-the-counter option?

Cromin's is classified as a systemic hemostatic agent, and its official designation is a prescription-only medicine. The medicine’s designation as prescription-only reflects its systemic mechanism, which requires the professional oversight of a healthcare provider for its appropriate use.

Q: Is Cromin's a narcotic or addictive substance?

Official product information confirms that the active ingredient, Carbazochrome, is not classified as a scheduled controlled substance by major international regulatory bodies.

Q: Is there a generic version of Cromin's available?

Yes, the drug's generic name is Carbazochrome. This ingredient is manufactured and sold by various companies under multiple different brand names in different regions globally.

Q: Is the purpose of Cromin's to cure the condition or manage symptoms?

The official therapeutic use of Cromin’s is described as assisting in the management and prevention of various types of bleeding disorders. Regulatory definitions align its purpose with maintaining capillary integrity and supporting the management of symptoms, rather than providing a permanent cure.

Q: Is Cromin's used in countries outside of the US/EU?

Yes, regulatory and commercial databases confirm that the drug, or its various brand-name forms, is documented for use in several countries across Asia, South America, and the Middle East, in addition to being referenced in Japanese drug information sheets.

How should Cromin's be stored and disposed of?

Official Storage and Disposal Profile

Prescription medications like Cromin's must be stored and disposed of according to strict governmental regulations to maintain drug integrity and prevent misuse or accidental exposure. Official labeling generally mandates storage at a specific temperature, often controlled room temperature, in a location protected from excessive light or moisture.

Storage Requirements

Requirement	Guidance
Temperature	Store at the temperature specified on the label, typically controlled room temperature.
Security	Keep out of the reach and sight of children and pets; secure controlled substances in a locked area.
Container	Keep in the original container with the safety closure tightly secured.
Condition	Outdated or damaged product must be quarantined and separated from usable stock.

Disposal Instructions

The primary method for disposal is through an authorized drug take-back program (e.g., DEA-sponsored sites). If a take-back program is unavailable, the product must be mixed with an unpalatable substance (like dirt or coffee grounds), placed in a sealed bag, and discarded with household trash. Flushing is generally reserved for a limited number of medicines designated by regulatory agencies as highly dangerous with a single accidental dose.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Peru

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z